These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21846426)

  • 21. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.
    Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F
    J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.
    Mitchell AJ; Vancampfort D; Sweers K; van Winkel R; Yu W; De Hert M
    Schizophr Bull; 2013 Mar; 39(2):306-18. PubMed ID: 22207632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.
    Laugharne J; Waterreus AJ; Castle DJ; Dragovic M
    Australas Psychiatry; 2016 Feb; 24(1):62-6. PubMed ID: 26635377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study.
    Jennex A; Gardner DM
    Can J Psychiatry; 2008 Jan; 53(1):34-42. PubMed ID: 18286870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics.
    DelMonte MT; Bostwick JR; Bess JD; Dalack GW
    J Clin Pharm Ther; 2012 Dec; 37(6):668-73. PubMed ID: 22845616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
    Bushe CJ; Bradley AJ; Doshi S; Karagianis J
    Int J Clin Pract; 2009 Dec; 63(12):1743-61. PubMed ID: 19840151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
    Pallava A; Chadda RK; Sood M; Lakshmy R
    Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient, Treatment, and Health Care Utilization Variables Associated with Adherence to Metabolic Monitoring Practices in Children and Adolescents Taking Second-Generation Antipsychotics.
    Coughlin M; Goldie CL; Tranmer J; Khalid-Khan S; Tregunno D
    Can J Psychiatry; 2018 Apr; 63(4):240-249. PubMed ID: 29528720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
    Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
    Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.
    Robinson DG; Schooler NR; Correll CU; John M; Kurian BT; Marcy P; Miller AL; Pipes R; Trivedi MH; Kane JM
    Am J Psychiatry; 2018 Feb; 175(2):169-179. PubMed ID: 28945118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of cardiovascular risk in an Italian psychiatric outpatient sample: A chart review of patients treated with second-generation antipsychotics.
    Severi E; Ferrara M; Tedeschini E; Vacca F; Mungai F; Amendolara R; Baccari F; Starace F
    Int J Ment Health Nurs; 2018 Jun; 27(3):1002-1008. PubMed ID: 29197134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study.
    Mangurian C; Schillinger D; Newcomer JW; Vittinghoff E; Essock S; Zhu Z; Dyer W; Schmittdiel J
    J Gen Intern Med; 2018 Jan; 33(1):79-86. PubMed ID: 29090381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers.
    Wakefield S; Aligeti M; Rachamallu V; Baronia R; Aynampudi R; Parmar A; Peterson P; Masodkar K
    Am J Ther; 2020; 27(5):e425-e430. PubMed ID: 30762589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic monitoring for patients treated with antipsychotic medications.
    Cohn TA; Sernyak MJ
    Can J Psychiatry; 2006 Jul; 51(8):492-501. PubMed ID: 16933586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study.
    Mitchell AJ; Vancampfort D; Manu P; Correll CU; Wampers M; van Winkel R; Yu W; De Hert M
    PLoS One; 2019; 14(9):e0210674. PubMed ID: 31513598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical health management in psychiatric settings.
    De Hert M; van Winkel R; Silic A; Van Eyck D; Peuskens J
    Eur Psychiatry; 2010 Jun; 25 Suppl 2():S22-8. PubMed ID: 20620882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
    Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
    Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial/Ethnic disparities in monitoring metabolic parameters for patients with schizophrenia receiving antipsychotic medications.
    Phillips KL; Copeland LA; Zeber JE; Stock EM; Tsan JY; MacCarthy AA
    Am J Geriatr Psychiatry; 2015 Jun; 23(6):596-606. PubMed ID: 25154537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.